IRIS
CARLOMAGNO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.071
NA - Nord America 3.470
EU - Europa 3.028
SA - Sud America 511
AF - Africa 94
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.182
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.318
SG - Singapore 1.845
RU - Federazione Russa 1.220
VN - Vietnam 819
IT - Italia 788
CN - Cina 684
BR - Brasile 410
HK - Hong Kong 320
DE - Germania 205
FR - Francia 162
UA - Ucraina 144
FI - Finlandia 143
CA - Canada 104
IE - Irlanda 95
GB - Regno Unito 92
IN - India 90
JP - Giappone 59
NL - Olanda 58
BD - Bangladesh 53
AR - Argentina 37
IQ - Iraq 35
SE - Svezia 31
PH - Filippine 30
ZA - Sudafrica 26
MX - Messico 25
PL - Polonia 24
CI - Costa d'Avorio 22
KR - Corea 18
ES - Italia 17
TH - Thailandia 17
CO - Colombia 14
EC - Ecuador 13
TR - Turchia 13
PK - Pakistan 12
VE - Venezuela 12
AT - Austria 11
ID - Indonesia 11
LT - Lituania 10
AZ - Azerbaigian 8
MA - Marocco 8
TW - Taiwan 8
CL - Cile 7
PY - Paraguay 7
GE - Georgia 6
KE - Kenya 6
NP - Nepal 6
UZ - Uzbekistan 6
AU - Australia 5
TN - Tunisia 5
UY - Uruguay 5
AL - Albania 4
HN - Honduras 4
JM - Giamaica 4
MY - Malesia 4
OM - Oman 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
HR - Croazia 3
IL - Israele 3
LY - Libia 3
PA - Panama 3
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
EU - Europa 2
GR - Grecia 2
GT - Guatemala 2
JO - Giordania 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NG - Nigeria 2
PE - Perù 2
QA - Qatar 2
RO - Romania 2
SA - Arabia Saudita 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
CV - Capo Verde 1
DK - Danimarca 1
GA - Gabon 1
GD - Grenada 1
GN - Guinea 1
GY - Guiana 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 11.167
Salva come PNG Salva come JPEG
Città #
Singapore 776
San Jose 573
Moscow 313
Hong Kong 302
Ashburn 243
Ho Chi Minh City 241
Naples 240
Chandler 237
Beijing 206
Hanoi 194
Jacksonville 145
Santa Clara 123
The Dalles 118
Lauterbourg 107
Millbury 100
Princeton 98
Los Angeles 95
Napoli 79
Munich 68
Nanjing 66
Buffalo 59
Boston 54
Ottawa 53
Wilmington 50
Hefei 47
Tokyo 47
Amsterdam 45
New York 43
São Paulo 42
Haiphong 34
Dallas 33
Da Nang 32
Redondo Beach 31
Nanchang 29
Montreal 28
Woodbridge 25
Orem 24
Helsinki 23
Chicago 22
Turku 22
Warsaw 21
Salerno 20
Chennai 19
Des Moines 19
Brooklyn 18
Shenyang 18
Augusta 17
Rome 17
Frankfurt am Main 16
Shanghai 16
Atlanta 15
Hebei 15
Hải Dương 15
Lawrence 15
Nocera Superiore 15
Poplar 15
London 14
Rio de Janeiro 14
Baghdad 13
Falls Church 13
Mexico City 13
Milan 13
Nuremberg 13
Boardman 12
Giugliano in Campania 12
Houston 12
Kronberg 12
Kunming 12
Seattle 12
Ann Arbor 11
Changsha 11
Manchester 11
Ninh Bình 11
Thái Bình 11
Hangzhou 10
Tianjin 10
Waldbuttelbrunn 10
Biên Hòa 9
Can Tho 9
Denver 9
Kochi 9
Mumbai 9
Phoenix 9
San Mateo 9
Toronto 9
Washington 9
Brasília 8
Düsseldorf 8
Erbil 8
Guarulhos 8
Johannesburg 8
Nha Trang 8
Nola 8
Seoul 8
Stockholm 8
Thái Nguyên 8
Acerra 7
Belo Horizonte 7
Capaccio 7
Charlotte 7
Totale 5.777
Salva come PNG Salva come JPEG
Nome #
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms 245
NCOA4 links iron bioavailability to DNA metabolism 181
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms 178
Mechanisms of RET mediated signal transduction 170
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase 164
NCOA4 inhibits initiation of DNA replication to maintain genome stability 156
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 155
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes 146
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology 146
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 145
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 142
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases 142
NCOA4 Deficiency Impairs Systemic Iron Homeostasis 138
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease 135
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology 134
Molecular biology of the MEN2 gene 133
Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis 132
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 130
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 129
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 129
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STING 128
Different mutations of the RET gene cause different human tumoral diseases. 126
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 126
NCOA4 Links Iron Bioavailability to DNA Metabolism 123
Ret gene fusions in malignancies of the thyroid and other tissues 123
Ret-mediated mitogenesis requires Src kinase activity. 119
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. 119
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 119
BAY 43-9006 inhibition of oncogenic RET mutants 118
Molecular mechanisms of RET activation in human cancer 118
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. 118
The extent of linkage disequilibrium in four populations with distinct demographic histories 114
The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia 113
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24 109
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 108
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 108
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE 107
I geni oncosoppressori in "Patologia Generale" IV Ed, Pontieri-Russo-Frati 107
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer 106
Constitutive and AP20187-induced ret activation in photoreceptors does not protect from light-induced damage 105
Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis 105
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model 105
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 104
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) 103
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 103
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose 103
BRAF is a therapeutic target in aggressive thyroid carcinoma. 102
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice 100
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. 98
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 97
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret 97
Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities 97
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation 97
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 96
Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism 96
Different mutations of the RET gene cause different human tumoral diseases. 94
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. 91
Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. 91
Iron and ferritin modulate MHC Class i expression and NK cell recognition 91
POR Campania FESR SATIN 89
RET\PTC activation in human thyroid carcinomas 88
Attacking cancer with molecularly targeted agents 88
Activation of RET oncogene and thyroid carcinogenesis 87
Molecular mechanisms of RET activation in human cancer. 87
Ret-mediated mitogenesis requires Src kinase activity. 86
Benzimidazole Analogues and related methods 86
Molecular mechanisms of RET activation in human neoplasia 85
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 84
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 83
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 82
Molecular mechanisms of RET activation in human neoplasia. 82
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation 82
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B 81
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 81
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. 79
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. 78
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affaected by familial medullary thyroid carcinoma. 76
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. 75
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. 75
Oncogenic rearrangements driving ionizing radiation-associated human cancer 75
Central role of RET in thyroid cancer 75
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. 74
Ret-mediated mitogenesis requires Src kinase activity 73
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. 72
Receptor tyrosine kinases as targets for anticancer therapeutics 71
POINT MUTATION OF THE RET PROTO-ONCOGENE IN THE TT HUMAN MEDULLARY THYROID CARCINOMA CELL LINE 71
Molecular targeting of the RET kinase in thyroid cancer 71
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. 70
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. 69
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 69
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application 69
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A 68
Receptor tyrosine kinase inhibitors in thyroid cancer. 66
Minireview:RET:normal and abnormal functions 66
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma 64
Ret-mediated mitogenesis requires Src kinase activity. 64
Molecular Mechanism of RET in Human Cancer 63
Ret-mediated mitogenesis requires Src kinase activity 63
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 63
The Human Eps15 gene encoding a tyrosine kinase substrate is conserved in evolution and map to 1p31-1p32 62
Totale 10.306
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.946
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.946
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202186 0 0 0 0 0 0 0 0 0 3 73 10
2021/2022600 9 3 17 3 5 20 25 31 103 36 119 229
2022/2023643 123 49 5 52 76 65 10 54 92 60 42 15
2023/2024568 22 93 62 48 44 53 22 54 16 8 110 36
2024/20252.917 162 218 25 25 58 144 355 198 215 307 910 300
2025/20265.341 714 369 536 529 907 220 686 292 730 358 0 0
Totale 11.352